血栓治療市場は、予測期間中に 6.84% という堅調な CAGR を遂げる見込みです。市場の発展に影響を与える要因は、外傷の発生率の上昇と、市場の発展を支える座りがちな生活様式の受容の拡大です。
血栓が下限に配置される最も広く認識されている理由の 1 つは損傷であると考えられています。静脈が損傷すると、周囲の血液が濃くなり、凝固が起こります。その後、損傷による静脈の損傷により血栓が発生する可能性があります。外傷、特に路上事故の増加によって、血栓治療の普及が促進されています。 2018年6月のWHOによると、世界中で約130万人が路上事故で命を落としています。さらに、2019 年に世界中で新たに登録された骨折症例数は 1 億 7,800 万件あり、1990 年頃から 33.4% 増加しました。長期に渡る休養による副作用の絶対的な蔓延は、2910 年ごとに 4 億 5,500 万件に達し、1990 年頃から 67.5% 増加しました。 骨折が脳卒中のもう 1 つの典型的な原因です。その結果、外傷の増加により、血栓治療に対する市場の関心が高まっています。
目次
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING INCIDENCE OF TRAUMA CASES
4.2.2 RISING ADOPTION OF SEDENTARY LIFESTYLE
4.3 RESTRAINTS
4.3.1 RISKS ASSOCIATED WITH THROMBOSIS DRUGS
4.4 OPPORTUNITIES
4.4.1 NEW PRODUCT APPROVALS AND LAUNCHES
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION AND SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL THROMBUS TREATMENT MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON PRODUCTION
5.3.3 DEMAND-SUPPLY GAP ANALYSIS
5.3.4 IMPACT ON PRICING
5.4 NUMBER OF PROCEDURES FOR PULMONARY EMBOLISM
6 GLOBAL THROMBUS TREATMENT MARKET, BY TYPE
6.1 OVERVIEW
6.2 ATRIAL THROMBUS
6.3 VENOUS THROMBUS
7 GLOBAL THROMBUS TREATMENT MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 MEDICAL THERAPY
7.3 SURGERY
7.4 OTHERS
8 GLOBAL THROMBUS TREATMENT MARKET, BY REGION
8.1 OVERVIEW
8.1.1 NORTH AMERICA
8.1.1.1 US
8.1.1.2 CANADA
8.1.2 EUROPE
8.1.2.1 GERMANY
8.1.2.2 UK
8.1.2.3 FRANCE
8.1.2.4 ITALY
8.1.2.5 SPAIN
8.1.2.6 REST OF EUROPE
8.1.3 ASIA-PACIFIC
8.1.3.1 JAPAN
8.1.3.2 CHINA
8.1.3.3 INDIA
8.1.3.4 AUSTRALIA
8.1.3.5 SOUTH KOREA
8.1.3.6 REST OF ASIA-PACIFIC
8.1.4 REST OF THE WORLD
8.1.4.1 MIDDLE EAST
8.1.4.2 AFRICA
8.1.4.3 LATIN AMERICA
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPETITIVE BENCHMARKING
9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL THROMBUS TREATMENT MARKET
9.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL THROMBUS TREATMENT MARKET
9.5 KEY DEVELOPMENT ANALYSIS
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
9.6.1 PRODUCT APPROVALS/PRODUCT LAUNCHES
9.6.2 PARTNERSHIP/COLLABORATION
9.7 MAJOR PLAYERS FINANCIAL MATRIX
9.7.1 SALES (USD MILLION), 2021
9.7.2 R&D (USD MILLION), 2021
10 COMPANY PROFILES
10.1 TEVA PHARMACEUTICAL INDUSTRIES LTD.
10.1.1 COMPANY OVERVIEW
10.1.2 FINANCIAL ANALYSIS
10.1.3 PRODUCTS OFFERED
10.1.4 KEY DEVELOPMENTS
10.1.5 SWOT ANALYSIS
10.1.6 KEY STRATEGIES
10.2 SANOFI
10.2.1 COMPANY OVERVIEW
10.2.2 FINANCIAL OVERVIEW
10.2.3 PRODUCTS OFFERED
10.2.4 KEY DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.2.6 KEY STRATEGIES
10.3 PFIZER INC.
10.3.1 COMPANY OVERVIEW
10.3.2 FINANCIAL OVERVIEW
10.3.3 PRODUCTS OFFERED
10.3.4 KEY DEVELOPMENTS
10.3.5 SWOT ANALYSIS
10.3.6 KEY STRATEGIES
10.4 BAYER AG
10.4.1 COMPANY OVERVIEW
10.4.2 FINANCIAL OVERVIEW
10.4.3 PRODUCTS OFFERED
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIES
10.5 ANGIODYNAMICS.
10.5.1 COMPANY OVERVIEW
10.5.2 FINANCIAL OVERVIEW
10.5.3 PRODUCTS OFFERED
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIES
10.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
10.6.1 COMPANY OVERVIEW
10.6.2 FINANCIAL OVERVIEW
10.6.3 PRODUCTS OFFERED
10.6.4 KEY DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.6.6 KEY STRATEGIES
10.7 BRISTOL-MYERS SQUIBB COMPANY
10.7.1 COMPANY OVERVIEW
10.7.2 FINANCIAL OVERVIEW
10.7.3 PRODUCTS OFFERED
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIES
10.8 ASPEN HOLDINGS
10.8.1 COMPANY OVERVIEW
10.8.2 FINANCIAL OVERVIEW
10.8.3 PRODUCTS OFFERED
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIES
10.9 JOHNSON & JOHNSON SERVICES, INC.
10.9.1 COMPANY OVERVIEW
10.9.2 FINANCIAL OVERVIEW
10.9.3 PRODUCTS OFFERED
10.9.4 KEY DEVELOPMENTS
10.9.5 SWOT ANALYSIS
10.9.6 KEY STRATEGIES
10.10 DAIICHI SANKYO COMPANY, LIMITED
10.10.1 COMPANY OVERVIEW
10.10.2 FINANCIAL OVERVIEW
10.10.3 PRODUCTS OFFERED
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIES
11 APPENDIX
11.1 REFERENCES
11.2 RELATED REPORTS
